CN115770230A - 一种靶向纳米分子探针及其在制备肿瘤治疗药物中的应用 - Google Patents
一种靶向纳米分子探针及其在制备肿瘤治疗药物中的应用 Download PDFInfo
- Publication number
- CN115770230A CN115770230A CN202211439929.5A CN202211439929A CN115770230A CN 115770230 A CN115770230 A CN 115770230A CN 202211439929 A CN202211439929 A CN 202211439929A CN 115770230 A CN115770230 A CN 115770230A
- Authority
- CN
- China
- Prior art keywords
- tumor
- tim3
- mns
- melanin
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 47
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 239000003068 molecular probe Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 5
- 230000008685 targeting Effects 0.000 title abstract description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 50
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 36
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 36
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 36
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 36
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 28
- 108020003175 receptors Proteins 0.000 claims abstract description 13
- 102000005962 receptors Human genes 0.000 claims abstract description 13
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims abstract description 10
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims abstract description 10
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 41
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 32
- 229960005277 gemcitabine Drugs 0.000 claims description 27
- 229920001223 polyethylene glycol Polymers 0.000 claims description 26
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 239000002077 nanosphere Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 8
- 229960001756 oxaliplatin Drugs 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 4
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 4
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 4
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 229960001149 dopamine hydrochloride Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000005336 cracking Methods 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002776 aggregation Effects 0.000 abstract description 9
- 238000004220 aggregation Methods 0.000 abstract description 9
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 6
- 102100031351 Galectin-9 Human genes 0.000 abstract description 4
- 101001130151 Homo sapiens Galectin-9 Proteins 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 102000037978 Immune checkpoint receptors Human genes 0.000 abstract description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 230000002018 overexpression Effects 0.000 abstract description 2
- 229940126585 therapeutic drug Drugs 0.000 abstract description 2
- 230000005909 tumor killing Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 101150106931 IFNG gene Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002088 nanocapsule Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002791 cell membrane marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211439929.5A CN115770230B (zh) | 2022-11-17 | 2022-11-17 | 一种靶向纳米分子探针及其在制备肿瘤治疗药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211439929.5A CN115770230B (zh) | 2022-11-17 | 2022-11-17 | 一种靶向纳米分子探针及其在制备肿瘤治疗药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115770230A true CN115770230A (zh) | 2023-03-10 |
CN115770230B CN115770230B (zh) | 2024-04-02 |
Family
ID=85389451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211439929.5A Active CN115770230B (zh) | 2022-11-17 | 2022-11-17 | 一种靶向纳米分子探针及其在制备肿瘤治疗药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115770230B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110456054A (zh) * | 2019-08-13 | 2019-11-15 | 臻悦生物科技江苏有限公司 | 胰腺癌检测试剂、试剂盒、装置及应用 |
US20210220480A1 (en) * | 2015-12-21 | 2021-07-22 | Gholam A. Peyman | Cancer Treatment And Imaging Methods Using Thermotherapy And Drug Delivery |
CN113769106A (zh) * | 2021-08-13 | 2021-12-10 | 深圳湾实验室 | 用于肿瘤免疫治疗的融合细胞膜纳米囊泡、其制备方法及应用 |
CN114404571A (zh) * | 2022-01-20 | 2022-04-29 | 中山大学·深圳 | 一种装载化疗药物且tigit过表达的工程化载药细胞膜囊泡以及制备方法和应用 |
CN115120572A (zh) * | 2022-06-28 | 2022-09-30 | 福建医科大学孟超肝胆医院(福州市传染病医院) | 一种基因工程化细胞膜涂层脂质体纳米囊泡及其制备与应用 |
-
2022
- 2022-11-17 CN CN202211439929.5A patent/CN115770230B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210220480A1 (en) * | 2015-12-21 | 2021-07-22 | Gholam A. Peyman | Cancer Treatment And Imaging Methods Using Thermotherapy And Drug Delivery |
CN110456054A (zh) * | 2019-08-13 | 2019-11-15 | 臻悦生物科技江苏有限公司 | 胰腺癌检测试剂、试剂盒、装置及应用 |
CN113769106A (zh) * | 2021-08-13 | 2021-12-10 | 深圳湾实验室 | 用于肿瘤免疫治疗的融合细胞膜纳米囊泡、其制备方法及应用 |
CN114404571A (zh) * | 2022-01-20 | 2022-04-29 | 中山大学·深圳 | 一种装载化疗药物且tigit过表达的工程化载药细胞膜囊泡以及制备方法和应用 |
CN115120572A (zh) * | 2022-06-28 | 2022-09-30 | 福建医科大学孟超肝胆医院(福州市传染病医院) | 一种基因工程化细胞膜涂层脂质体纳米囊泡及其制备与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115770230B (zh) | 2024-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zheng et al. | Her2-targeted multifunctional nano-theranostic platform mediates tumor microenvironment remodeling and immune activation for breast cancer treatment | |
Bellat et al. | Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme‐Induced Local Retention Properties | |
CN109666695B (zh) | 一种靶向整合素αvβ3的外泌体载体及其制备方法和应用 | |
US20180200194A1 (en) | Decoy nanoparticles to disrupt cancer cell-stromal cell networks | |
Zhu et al. | Identification and imaging of miR-155 in the early screening of lung cancer by targeted delivery of octreotide-conjugated chitosan-molecular beacon nanoparticles | |
EP3834844A1 (en) | AMYLOID ß SHORT PEPTIDE MEDIATED BRAIN TARGETED DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOF | |
Li et al. | iRGD peptide-mediated liposomal nanoparticles with photoacoustic/ultrasound dual-modality imaging for precision theranostics against hepatocellular carcinoma | |
CN114404571A (zh) | 一种装载化疗药物且tigit过表达的工程化载药细胞膜囊泡以及制备方法和应用 | |
EP3223016B1 (en) | Peptides for targeting gastric cancer, and medical use thereof | |
Jing et al. | Engineering goat milk-derived extracellular vesicles for multiple bioimaging-guided and photothermal-enhanced therapy of colon cancer | |
DE102004054536A1 (de) | Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel | |
CN109745326B (zh) | 一种包含吉非替尼和组蛋白去乙酰酶抑制剂的药物组合物,其脂质体制剂及其制药用途 | |
CN115770230A (zh) | 一种靶向纳米分子探针及其在制备肿瘤治疗药物中的应用 | |
Xu et al. | Sendai virus acts as a nano-booster to excite dendritic cells for enhancing the efficacy of CD47-directed immune checkpoint inhibitors against breast carcinoma | |
Zhan et al. | GMBP1-conjugated manganese oxide nanoplates for in vivo monitoring of gastric cancer MDR using magnetic resonance imaging | |
CN110448700B (zh) | 一种用于靶向诊疗胃癌的纳米载药复合物及制备方法 | |
CN114366822A (zh) | 一种主动靶向多模态分子影像探针及其制备方法和应用 | |
CN114869911A (zh) | Pd-1细胞膜纳米囊泡联合干细胞膜片在恶性黑色素瘤术后治疗中的应用 | |
Jeong et al. | Cancer Selective Turn-On Fluorescence Imaging Using a Biopolymeric Nanocarrier | |
CN114621325A (zh) | 一种纤连蛋白靶向多肽及其在促进肿瘤失巢凋亡及化疗增敏中的应用 | |
CN113499318A (zh) | 红细胞膜包被载药纳米粒/探针及其在脑胶质母细胞瘤诊疗中的应用 | |
CN114191539A (zh) | 一种复合共载送小分子核酸和活性蛋白的外泌体纳米粒子及其制备方法和应用 | |
CN114748424A (zh) | 一种脂质体递药体系及其制备方法和用途 | |
CN109568289B (zh) | 胎盘样硫酸软骨素a靶向传输系统及其制备方法和应用 | |
CN114010803B (zh) | 一种检测活体肿瘤微环境中Treg细胞的多功能靶向分子探针及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Zining Inventor after: Cai Xiangyi Inventor after: Cao Xiongfeng Inventor after: Zhu Haitao Inventor after: Pu Xufeng Inventor after: Zhang Heng Inventor before: Zhang Zining Inventor before: Cai Xiangyi Inventor before: Cao Xiongfeng Inventor before: Zhu Haitao Inventor before: Pu Xufeng Inventor before: Zhang Heng |
|
GR01 | Patent grant | ||
GR01 | Patent grant |